 |
|
Interchangeability of Conjugated Haemophilus influenzae Type b Vaccines in Infants
Edwin L. Anderson, MD;
Michael D. Decker, MD, MPH;
Janet A. Englund, MD;
Kathryn M. Edwards, MD;
Porter Anderson, PhD;
Pamela Mclnnes, DDS, MSC;
Robert B. Belshe, MD
JAMA. 1995;273(11):849-853.
Abstract
| |
Objective.
—To evaluate the safety and immunogenicity of two Haemophilus influenzae type b (Hib) conjugate vaccines when administered in serial combination. These vaccines consisted of Hib capsular polysaccharide polyribosyl-ribitol phosphate (PRP) conjugated to the meningococcal outer membrane protein (OMP) complex (PRP-OMP) and H influenzae oligosaccharide conjugated to a mutant toxin (CRM197) isolated from Corynebacterium diphtheriae (HbOC).
Design.
—Randomized, double-blind, clinical trial evaluating five Hib vaccination regimens.
Setting.
—Vaccine Treatment and Evaluation Units and affiliated private pediatric practices at Saint Louis (Mo) University, Vanderbilt University, Nashville, Tenn, and Baylor College of Medicine, Houston, Tex.
Patients.
—A total of 497 healthy 2-month-old infants scheduled to receive routine immunization.
Intervention.
—Participants received either PRP-OMP or HbOC given as recommended by the manufacturer, PRP-OMP at 2 and 6 months, HbOC at 2 months, then PRP-OMP at 4 and 6 months, or PRP-OMP at 2 months and then HbOC at 4 and 6 months. Unconjugated PRP was given at 15 months to evaluate priming.
Results.
—Geometric mean antibody concentrations differed significantly among the groups following the second and third immunizations of the primary series and following booster immunization with unconjugated PRP. On each occasion, the groups receiving serial combinations of PRP-OMP and HbOC achieved mean antibody concentrations that equalled or exceeded those of the groups receiving a single product. Adverse reactions did not vary by group.
Conclusions.
—The studied sequential combinations of Hib vaccines were safe and at least as immunogenic as either vaccine alone.
(JAMA. 1995;273:849-853)
Author Affiliations
| |
From the Division of Infectious Diseases, Departments of Medicine and Pediatrics (Drs E. L. Anderson and Belshe), Saint Louis (Mo) University School of Medicine; the Departments of Preventive Medicine (Dr Decker), Medicine (Dr Decker), and Pediatrics (Dr Edwards), Vanderbilt University School of Medicine, Nashville, Tenn; the Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Tex (Dr Englund); the Department of Pediatrics, University of Rochester (NY) School of Medicine (Dr P. Anderson); and the Respiratory Diseases Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Disease, Bethesda, Md (Dr Mclnnes). Drs Decker and Edwards have received honoraria from Lederle-Praxis Biologicals for speaking. Dr P. Anderson is a consultant to and stockholder in the manufacturer of one of the vaccines studied, but his role (the antibody assay) was done on coded specimens and he had no contact with the data decoding, data processing, or input on recommendations.
Footnotes
Reprint requests to Saint Louis University Health Sciences Center, Division of Infectious Diseases, 3635 Vista Ave, FDT-8N, PO Box 15250, St Louis, MO 63110 (Dr E. L. Anderson).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Vaccine Interchangeability
Greenberg and Feldman
CLIN PEDIATR 2003;42:93-99.
ABSTRACT
Active Immunization in the United States: Developments over the Past Decade
Dennehy
Clin. Microbiol. Rev. 2001;14:872-908.
ABSTRACT
| FULL TEXT
Combination Vaccines for Childhood Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP)
Committee on Infectious Diseases, 1998MIHNEAndash1 et al.
Pediatrics 1999;103:1064-1077.
FULL TEXT
Recommended Childhood Immunization Schedule---United States, January-December 1998
Committee on Infectious Diseases
Pediatrics 1998;101:154-157.
FULL TEXT
Lot-Release Criteria, Postlicensure Quality Control. and the Haemophilus influenzae Type b Conjugate Vaccines
Egan et al.
JAMA 1995;273:888-889.
ABSTRACT
|
